ECSP045048A - NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI- 5 (4-METHYLIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING - Google Patents

NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI- 5 (4-METHYLIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING

Info

Publication number
ECSP045048A
ECSP045048A ECSP045048A ECSP045048A EC SP045048 A ECSP045048 A EC SP045048A EC SP045048 A ECSP045048 A EC SP045048A EC SP045048 A ECSP045048 A EC SP045048A
Authority
EC
Ecuador
Prior art keywords
sulfonyl
dihydro
citrate
phenyl
methyl
Prior art date
Application number
Other languages
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045048A publication Critical patent/ECSP045048A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está dirigida a un nuevo producto farmacéutico y a su proceso de fabricación. Más particularmente, la presente invención se refiere a una nueva forma sólida de dosificación oral que contiene 5- [2-etoxi- 5(4-metilpiperazin-1-il sulfonil) fenil]-1,6-dihidro -1-metil-3-propil pirazolo [4,3-d] pirimidin-7-ona citrato, como agente activo, en compañía de excipientes farmacéuticamente aceptables, entregados en tabletas masticables, y al proceso de fabricación de estas formas de dosificación.The present invention is directed to a new pharmaceutical product and its manufacturing process. More particularly, the present invention relates to a novel solid oral dosage form containing 5- [2-ethoxy-5 (4-methylpiperazin-1-yl sulfonyl) phenyl] -1,6-dihydro -1-methyl-3 -propyl pyrazolo [4,3-d] pyrimidin-7-one citrate, as an active agent, in the company of pharmaceutically acceptable excipients, delivered in chewable tablets, and to the manufacturing process of these dosage forms.

ECSP045048 2003-04-09 2004-04-06 NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI- 5 (4-METHYLIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING ECSP045048A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CO03029961A CO5330617A1 (en) 2003-04-09 2003-04-09 NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI-5 (4-METHYLPIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING

Publications (1)

Publication Number Publication Date
ECSP045048A true ECSP045048A (en) 2004-05-28

Family

ID=40435089

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP045048 ECSP045048A (en) 2003-04-09 2004-04-06 NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI- 5 (4-METHYLIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING

Country Status (4)

Country Link
CO (1) CO5330617A1 (en)
EC (1) ECSP045048A (en)
GT (1) GT200400059A (en)
PE (1) PE20050017A1 (en)

Also Published As

Publication number Publication date
CO5330617A1 (en) 2003-10-31
PE20050017A1 (en) 2005-02-24
GT200400059A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
MXPA05007643A (en) Method for producing an immediately decomposing oral form of administration which releases active ingredients.
UY27277A1 (en) METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION OF LOW DOSE THAT HAS A UNIFORM DISTRIBUTION AND POWER OF THE DRUG
WO2006106514A3 (en) Electrospun dosage form and method of producing the same
WO2005046640A3 (en) Multi-site drug delivery platform
CY1112256T1 (en) PHARMACEUTICAL DOSAGE FORMING CONTAINERS AND METHOD OF PREPARATION
WO2008035020A3 (en) Galenic form for the trans-mucosal delivery of active ingredients
UY27886A1 (en) PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO.
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2005097076A3 (en) Low dose pharmaceutical products
AR034813A1 (en) PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
ECSP066553A (en) MASTICABLE ADMINISTRATION FORMS, NOT INDIVIDUALLY DOSED COMPRESSED.
ATE262893T1 (en) DOSAGE FORMS FOR THE TREATMENT OF ORAL MYCOSES
PA8548301A1 (en) PHARMACEUTICAL FORMULATION OF MASKED FLAVOR AND PROCEDURE FOR PREPARATION
SG160391A1 (en) Cladribine regimen for treating multiple sclerosis
ECSP045048A (en) NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI- 5 (4-METHYLIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING
TW200420304A (en) Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
MY153713A (en) A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate
MY141008A (en) Oral formulations of deoxypeganine and their uses
UY27596A1 (en) ORAL FORMULATION OF PURISIMATE FLUDARA WITH RAPID RELEASE OF INGREDIENT
PT1499278E (en) IMMEDIATE RELEASE PHARMACEUTICAL FORM FOR COMPOSITION OF TIBOLONE POLYMER
ECSP034769A (en) PHARMACEUTICAL COMPOSITION
ZA200509322B (en) Oral pharmaceutical formulations comprising acid-labile active ingredients and water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
CR7117A (en) METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION OF LOW DOSE THAT HAS A DISTRIBUTION AND POWER OF THE UNIFORM PHARMACO
ECSP024290A (en) PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
MY145885A (en) Controlled release formulations for oral administration